Cynthia A. Challener

Although limitations must be overcome, mass spectrometry is having a great impact on biologic development and manufacturing.

FDA issued approvals for less than half the number of new drugs in 2016 compared with 2015.

Alternatives to expensive palladium catalysts are gaining acceptance for commercial API synthesis.

As of mid-December, less than half the number of new drug approvals were issued by FDA in 2016 compared with 2015.

Previous hesitation by pharma industry to use cocrystals may change with FDA’s new guidance that classifies cocrystals APIs.

Non-precious-metal catalysts are increasingly employed for commercial API synthesis.

Pressures to accelerate current and next-gen therapies are challenging traditional microbiological testing models.

New catalysts show promise for pharmaceutical intermediate and API synthesis.

FDA redefines cocrystals as APIs and not drug-product intermediates.

A simpler, cost-effective method for the preparation of fluorolactams may be suitable for scale-up.

Researchers develop catalysts that mediate complex transformations under conditions appropriate for commercial manufacture.

Drug companies and CDMOs seeking greener routes to the production of complex APIs may look to biocatalysis.

Researchers at GlaxoSmithKline report a greener and lower-cost route to chiral fluorolactams that is suitable for scale up.

Recent research of efficient chiral synthesis technologies reveals potential uses in API manufacturing.

Enzymatic catalysis offers pharma manufacturers a way to implement the Principles of Green Chemistry.

Multiple methods are required for detecting and removing protein impurities.

Research efforts around the world are demonstrating that the application of flow chemistry for small-molecule API synthesis.

Recent chiral advances demonstrate promise for API synthesis.

Effective harvesting and purification processes play an essential role in ensuring that biopharmaceutical manufacturing processes provide biologic drug substances with uniform and consistent properties.

Application of flow chemistry for small-molecule API synthesis continues to expand thanks to research efforts.

Collaboration and single-use technologies aided the rapid scale-up of Ebola vaccine manufacturing

The production of antibody-drug conjugates requires biopharmaceutical and chemical manufacturing, and conjugation capabilities.

Bioprocess operations-from cell line selection to final filtration-can influence the consistency and purity of biologic drug substances.

Determining the appropriate amount and type of screening challenges drug developers when identifying relevant crystalline forms.

Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.

Gauging the adequate level and type of screening is the challenge when identifying relevant crystalline forms.

Scale-down modeling accelerates the development of downstream biopharma manufacturing processes.

Hazardous reagents can prove to be faster, simpler, cheaper, and greener.

Nanoscale catalysts and engineered nanoparticles show promise for API synthesis and delivery.

Scale-down modeling is instrumental in supporting the development of downstream biopharma manufacturing processes.